You're so right - there is no cause for concern. Most are holding from the $2 - $3 range, and are sitting on fabulous returns.
A re-rating in the $4 - $5 range is a 100% return. That's fair-value for a compound entering Phase III trials.
Anything over $5 is clearly overvalued at this point. The potential revenue of this drug - given that it is even approved - is being overstated.
You're so right - there is no cause for concern. Most are...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.30M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 45.0¢ | 44.5¢ | $157.9K | 353.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 303346 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 246671 | 10 |
View Market Depth
| Last trade - 15.32pm 24/07/2024 (20 minute delay) ? |
| PGL (ASX) Chart |